Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 255

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 255
---
 the above listed companies, BLAC also was introduced to several other companies in the biotech/healthcare/medtech industries during the period from February 15 to March 9, 2023, but a decision was made not to pursue discussions with them for several reasons, including industry sector, stage of development of intellectual property, science, treatment or therapy, company size, revenue, growth potential, stage of funding, etc. The companies included the following: “ Company G ”, a medical equipment manufacturer, which has developed a fully integrated, automated instrument that delivers high -throughput, quantitative, single -molecule, single -celldata with spatial context and subcellular resolution by bringing together advancements in imaging, fluidics, chemistry and bioinformatics. The company was introduced to BLAC on February 15, 2023 by a contact of OSR Holdings’ Sung Hoon Chung at a Seoul -basedearly seed venture capital investor. 150 “ Company H ”, a therapeutics company, focused on developing treatments for CNS disorders and rare diseases such as Alzheimer’s, which developed the first and only resveratrol product that safely reaches therapeutic levels without gastrointestinal side effects. The product has Orphan Drug Exclusivity and Patent Protection in Global Markets through 2036, with additional patents pending. The company was introduced to BLAC on February 18, 2023 by an asset management company that reached out directly to BLAC. “ Company I ”, which provides home healthcare, hospice & aftercare services in three states, with over 237 employees. Company services include (but are not limited to): post -operativecare; physical and speech therapy; pain management; hospice care; and funeral and burial services The company had over 97,000 patient encounters in 2022. The company was introduced to BLAC by an investment bank and wealth management firm, who reached out to BLAC directly on March 2, 2023. “ Company J ”, a therapeutics company, developing fetal neural stem cell therapeutic platform targeting neurological diseases such as Parkinson’s, Lou Gehrig’s, stroke, etc. The founder of the Company is a respected expert in the fetal stem cell space. The company was introduced to BLAC on February 28, 2023 by Jaechul Seo, a shareholder of OSR Holdings. “ Company K ”, a clinical stage biopharmaceutical company, focusing on clinical development of medicines in oncology, immunology, and geriatrics, including therapeutic cancer vaccines and